Neonc Technologies (NASDAQ:NTHI) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Neonc Technologies (NASDAQ:NTHI) released its quarterly earnings data on Tuesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.35), FiscalAI reports.

Neonc Technologies Stock Up 0.5%

Neonc Technologies stock opened at $7.04 on Tuesday. The business has a 50 day moving average of $9.11 and a 200-day moving average of $9.37. Neonc Technologies has a 1 year low of $3.20 and a 1 year high of $16.00.

Institutional Investors Weigh In On Neonc Technologies

A number of institutional investors have recently added to or reduced their stakes in NTHI. 683 Capital Management LLC acquired a new position in Neonc Technologies in the 4th quarter valued at approximately $442,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Neonc Technologies during the fourth quarter worth $126,000. Barclays PLC grew its stake in shares of Neonc Technologies by 5,314.8% in the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after purchasing an additional 8,982 shares during the last quarter. State Street Corp grew its stake in shares of Neonc Technologies by 9.9% in the fourth quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Neonc Technologies in the fourth quarter valued at $124,000.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Zacks Research upgraded shares of Neonc Technologies to a “hold” rating in a research report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neonc Technologies in a research note on Friday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Neonc Technologies presently has an average rating of “Reduce”.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.